Salarius Pharmaceuticals, Inc. financial data

Symbol
SLRX on Nasdaq
Location
2450 Holcombe Blvd, Suite J 608, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 157 % +382%
Return On Equity -401 % -186%
Return On Assets -156 % -47.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.86M shares +307%
Common Stock, Shares, Outstanding 944K shares -34.5%
Entity Public Float 1.5M USD -69.5%
Common Stock, Value, Issued 94 USD -34.7%
Weighted Average Number of Shares Outstanding, Basic 482K shares +464%
Weighted Average Number of Shares Outstanding, Diluted 482K shares +464%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 429K USD -34.5%
General and Administrative Expense 4.64M USD +1.7%
Operating Income (Loss) -5.07M USD +2.84%
Net Income (Loss) Attributable to Parent -5M USD -0.22%
Earnings Per Share, Basic 7 USD/shares +84.1%
Earnings Per Share, Diluted 7 USD/shares +84.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.81M USD +46.5%
Other Assets, Current 80.9K USD -32%
Assets, Current 6.06M USD +58.7%
Other Assets, Noncurrent 32.1K USD -12.1%
Assets 6.1M USD +58%
Accounts Payable, Current 1.1M USD +566%
Liabilities 1.85M USD +97.8%
Retained Earnings (Accumulated Deficit) -85.5M USD -6.22%
Stockholders' Equity Attributable to Parent 4.25M USD +45.3%
Liabilities and Equity 6.1M USD +58%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.18M USD +12.7%
Net Cash Provided by (Used in) Financing Activities 546K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 944K shares -34.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -636K USD +58.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.81M USD +46.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.09K USD +1.87%
Deferred Tax Assets, Valuation Allowance 17.1M USD +7.54%
Deferred Tax Assets, Gross 17.1M USD +7.54%
Deferred Tax Assets, Operating Loss Carryforwards 8.35M USD +35.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 89.7M USD +7.59%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.11K USD -0.09%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%